A.De JagerP
Researchers at the University of Pennsylvania analyzed health records from roughly 12,004 adults with Type 2 diabetes who started taking GLP-1 medications between 2019 and 2024, comparing them with tens of thousands of other patients using two other diabetes drugs, SGLT-2 inhibitors and DPP-4 inhibitors
Used responsibly under proper care, peptides can be a remarkable addition to a wellness plan
The pathogenesis of sarcopenia is complex and multifaceted: the chronic catabolic condition, increased energy expenditure, reduced appetite, side effects of multiple therapies, alterations in circulating levels of hormones, low protein synthesis, and the presence of ascites or portosystemic shunts are all factors contributing to muscle atrophy in cirrhotic patients [23]
Unlike oral supplements, which must pass through the digestive system, IV therapy delivers B12 directly into your bloodstream
A new option called orforglipron, a nonpeptide oral GLP-1, may be available in 2026